Innovation all for the patients

CHUGAI

Roche A member of the Roche group

Genentech Announces FDA Emergency Use Authorization for Chugai's Actemra for Hospitalized Patients with COVID-19

TOKYO, June 25, 2021 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Genentech issued a press release on June 24 (local time) regarding the Emergency Use Authorization by the US FDA for Actemra®, a humanized anti-human IL-6 receptor monoclonal antibody [generic name: tocilizumab (genetical recombination)] created by Chugai, for the treatment of COVID-19 in hospitalized adults and children.

Please refer to the link below for details of the press release:

- Genentech's Actemra Receives FDA Emergency Use Authorization for the Treatment of COVID-19 In Hospitalized Adults and Children

https://www.gene.com/media/press-releases/14917/2021-06-24/genentechs-actemra-receives-fda-emergenc

###

CHUGAI PHARMACEUTICAL CO., LTD. Corporate Communications Dept.
1-1, Nihonbashi-Muromachi 2-chome, Chuo-ku Tokyo, 103-8324 Japan
Media Relations Group TEL:+81-(0)3-3273-0881 E-mail:pr@chugai-pharm.co.jp
Investor Relations Group TEL:+81-(0)3-3273-0554 E-mail:ir@chugai-pharm.co.jp